Moderate certaintyPoints to benefit
Pimobendan in preclinical stage B2 disease
EPIC, 2016 · FDA NADA 141-273, 2025
Cardiology
Myxomatous mitral valve disease (dogs)
Low certaintyInconclusive
Does preclinical pimobendan shorten survival once heart failure develops?
McAulay, 2026 · Park, 2025
Moderate certaintyPoints to benefit
Pimobendan in congestive heart failure
QUEST, 2008
Appraisal in preparation
Moderate certaintyNo benefit shown
ACE inhibitors before heart failure
SVEP, 2002 · VETPROOF, 2007
Appraisal in preparation
Low certaintyPoints to benefit
Spironolactone added to standard heart-failure therapy
Bernay et al., 2010
Appraisal in preparation
Moderate certaintyNo benefit shown
Spironolactone with benazepril to delay the onset of heart failure
DELAY, 2020
No evidenceUntested